Related Experiment Video
Updated: May 7, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
Jeong Min Lee1,2, Won Hyeok Lee1,2, Seung Hyeon Cho1,2
1School of Biological Sciences, University of Ulsan, Ulsan, Korea.
Purpose:
Developmentally regulated GTP-binding protein 2 (DRG2) regulates microtubule dynamics and G2/M arrest during docetaxel treatment. Poly ADP-ribose polymerase (PARP) acts as an important repair system for DNA damage caused by docetaxel treatment. This study investigated whether DRG2 expression affects response to PARP inhibitors (olaparib) using prostate cancer cell lines PC3, DU145, LNCaP-FGC, and LNCaP-LN3.
Materials And Methods:
The cell viability and DRG2 expression levels were assessed using colorimetric-based cell viability assay and western blot. Cells were transfected with DRG2 siRNA, and pcDNA6/V5-DRG2 was used to overexpress DRG2. Flow cytometry was applied for cell cycle assay and apoptosis analysis using the Annexing V cell death assay.
Results:
The expression of DRG2 was highest in LNCaP-LN3 and lowest in DU145 cells. Expressions of p53 in PC3, DU145, and the two LNCaP cell lines were null-type, high-expression, and medium-expression, respectively. In PC3 (DRG2 high, p53 null) cells, docetaxel increased G2/M arrest without apoptosis; however, subsequent treatment with olaparib promoted apoptosis. In DU145 and LNCaP-FGC (DRG2 low), docetaxel increased sub-G1 but not G2/M arrest and induced apoptosis, whereas olaparib had no additional effect. In LNCaP-LN3 (DRG2 high, p53 wild-type), docetaxel increased sub-G1 and G2/M arrest, furthermore olaparib enhanced cell death. Docetaxel and olaparib combination treatment had a slight effect on DRG2 knockdown PC3, but increased apoptosis in DRG2-overexpressed DU145 cells.
Conclusions:
DRG2 and p53 expressions play an important role in prostate cancer cell lines treated with docetaxel, and DRG2 levels can predict the response to PARP inhibitors.
Insights
Developmentally regulated GTP-binding protein 2 (DRG2) expression levels influence prostate cancer cell response to docetaxel and PARP inhibitors. Higher DRG2 expression predicts a better response to olaparib, suggesting its potential as a predictive biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Developmentally regulated GTP-binding protein 2 (DRG2) is implicated in microtubule dynamics and cell cycle regulation.
- Poly ADP-ribose polymerase (PARP) inhibitors are utilized in cancer therapy, particularly for DNA repair deficiencies.
- Docetaxel treatment can induce DNA damage and cell cycle arrest, making it a relevant therapeutic agent in prostate cancer.
Purpose of the Study:
- To investigate the role of DRG2 expression in prostate cancer cell response to docetaxel and PARP inhibition with olaparib.
- To determine if DRG2 levels can predict treatment efficacy in prostate cancer cell lines.
- To explore the combined effects of docetaxel and olaparib in relation to DRG2 and p53 expression.
Main Methods:
- Cell viability assays and Western blotting were used to assess cell viability and DRG2 expression.
- Prostate cancer cell lines (PC3, DU145, LNCaP-FGC, LNCaP-LN3) were manipulated for DRG2 knockdown (siRNA) and overexpression (pcDNA6/V5-DRG2).
- Flow cytometry, including cell cycle and apoptosis analyses (Annexin V assay), was employed to evaluate treatment effects.
Main Results:
- DRG2 expression varied significantly across cell lines, being highest in LNCaP-LN3 and lowest in DU145.
- Docetaxel induced G2/M arrest or apoptosis depending on DRG2 and p53 status. Olaparib enhanced cell death in cells with high DRG2 expression (LNCaP-LN3) and in docetaxel-treated PC3 cells.
- DRG2 overexpression in DU145 cells increased apoptosis upon combination treatment, while DRG2 knockdown had minimal effect.
Conclusions:
- DRG2 and p53 expression levels are critical determinants of prostate cancer cell response to docetaxel and PARP inhibitors.
- DRG2 expression serves as a predictive biomarker for treatment response to PARP inhibitors like olaparib in prostate cancer.
- The interplay between DRG2, p53, and therapeutic agents offers potential avenues for personalized prostate cancer treatment strategies.
